Branded Generics Market Report 2026

Branded Generics Market Overview

• Branded Generics market size has reached to $393.5 billion in 2025 • Expected to grow to $653.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Rising Prevalence Of Chronic Diseases Propelling Growth In Branded Generics Market • Market Trend: Biocon Partners With Tabuk Pharmaceuticals To Expand Diabetes Treatment Solutions In The Middle East • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Branded Generics Market?

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are. The main drug classes of branded generics are alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and other drugs. The alkylating agents of branded generics refer to a subclass of antineoplastic or anticancer medications that work by preventing the conversion of DNA into RNA, which halts the creation of proteins. Alkylating chemicals change the hydrogen atoms on DNA to alkyl groups, which causes cross-links to form inside the DNA chain and has cytotoxic, mutagenic, and cancerous consequences. The various routes of administration of branded generics include topical, oral, parenteral, and other routes. They are in various medical conditions including oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and other diseases.

What Is The Branded Generics Market Growth Forecast?

The branded generics market size is expected to see rapid growth in the next few years. It will grow to $653.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to expansion of branded generics portfolio, adoption of digital marketing in pharma, increasing partnerships with healthcare providers, growth in emerging markets, advancements in drug formulation technologies. Major trends in the forecast period include increasing brand awareness among patients, marketing strategies focused on differentiation, growth in prescription volume for branded generics, rising physician preference for branded generics, expansion of emerging markets for generic drugs.

Global Branded Generics Market Segmentation

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs 2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration 3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications Subsegments: 1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds 2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues 3) By Hormones: Corticosteroids, Thyroid Hormones 4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers 5) By Lipid Lowering Drugs: Statins, Fibrates 6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) 7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics 8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs 9) By Other Drugs: Analgesics, Antibiotics, Antivirals

What Is The Driver Of The Branded Generics Market?

The increasing prevalence of chronic diseases is expected to drive the growth rate of branded generics market. Chronic diseases are long-lasting sicknesses that often cannot be healed; however, they are curable and controllable. Chronic diseases are increasing due to the increasing use of tobacco products, poor nutrition, physical inactivity, excessive use of alcohol, and others. Customers across the globe are more inclined toward branded generics to treat chronic diseases as they purchase them at a lower cost than usual medications. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal agency, in 2023, about 76.4% of U.S. adults reported having at least one of 12 selected chronic conditions, 51.4% of U.S. adults reported multiple chronic conditions. Thus, an increase in the prevalence of chronic diseases is driving the growth of branded generics industry.

Key Players In The Global Branded Generics Market

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Global Branded Generics Market Trends and Insights

Major companies operating in branded generics are entering into a partnership with relevant companies to leverage each other's resources and expand into new markets. For instance, in September 2024, Biocon Ltd., an India-based pharmaceutical company, partnered with Tabuk Pharmaceuticals. Biocon will be responsible for the development and manufacturing of the GLP-1 products, ensuring high-quality biopharmaceuticals tailored for diabetes treatment. Tabuk Pharmaceuticals will hold the marketing authorization rights and will manage the registration, importation, and promotion of these products across the Middle East, particularly in Saudi Arabia. The agreement includes provisions for future expansion into other GLP products beyond the initial offerings, allowing for a broader range of diabetes treatments. the partnership aims to deliver unique health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies' commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company and markets branded and generic pharmaceutical products.

What Are Latest Mergers And Acquisitions In The Branded Generics Market?

In May 2023, Yaral Pharma, a Switzerland-based pharmaceutical company, collaborated with Eversana Life Science Services LLC to develop its portfolio of pain and endocrinology products in the US by partnering with EVERSANA for comprehensive commercialization services, including logistics and operational support. Eversana Life Science Services LLC is a US-based company that provides comprehensive commercialization and consulting services for the life sciences industry.

Regional Insights

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Branded Generics Market?

The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Branded Generics Market Report 2026?

The branded generics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.